Clearmind Medicine Inc. (CMND) Form 6-K — Oct 27, 2026
Clearmind Medicine (Nasdaq: CMND) announced on October 27, 2026 that it completed patient recruitment for the first segment of Part B of its Phase I/IIa clinical trial of CMND-100 in moderate-to-severe Alcohol Use Disorder. Part B consists of two sequential single-dose ascending cohorts of 80 mg and 160 mg, each with six patients, assessing safety, tolerability, pharmacokinetics, and early efficacy signals including reductions in alcohol craving. This marks the company's first evaluation of CMND-100 in actual AUD patients after Part A in healthy volunteers. The trial is running at Johns Hopkins, Yale, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.
Key figures
- Cohort doses mg
- [80,160]
- Granted patents
- 32
- Patent families
- 19
- Patients per cohort
- 6
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.